By using this site you agree that cookies are used for purposes of analysis and relevance     Yes, I agree  No, I want more informations
首页 / 关于诺华赛 / 媒体与活动 / 新闻发布

新闻发布

Novasep presents the second successful year of its ‘back to basics’ strategy and preliminary 2015 financial results

Novasep presents the second successful year of its ‘back to basics’ strategy and preliminary 2015 financial results

02 3月 2016

- Solid 7% sales growth in 2015 (€266m)
- Strong EBITDA growth with a 15% increase to €31m


Novasep adds synthesis and kilo lab extensions to US facility

28 1月 2016

Enhanced capabilities bring Novasep’s unique range of specialized drug development technologies within easier reach of North American customers


Novasep and Advanced Biotherapeutics Consulting team up on Adeno-Associated Virus (AAV) vectors

Novasep and Advanced Biotherapeutics Consulting team up on Adeno-Associated Virus (AAV) vectors

13 1月 2016

Strategic partnership creates a world leading CDMO offer to supply AAV-based viral vectors, an increasingly attractive therapeutic platform for gene therapy


Novasep and CPI advance innovation in UK biopharmaceutical manufacturing

10 11月 2015

Novasep’s BioSC® Lab continuous biochromatography equipment will enable CPI to disseminate next-generation downstream processes


Novasep appoints two executives to further strengthen its management team

05 5月 2015

Pierre-Louis Mikus joins as chief legal officer; Bertrand Waymel is promoted to group human resources director


Novasep reports strong 2014 full year results

21 4月 2015

- Swift execution of ‘Back to Basics’ strategic plan leading to successful portfolio reshaping
- All business units contributing to the strong performance
- 20% EBITDA growth driven by focus on attractive projects and cost control policy



你可以停留在这一页,选择更多的宣传册或者你可以直接下载你选择的宣传册
FIXED_BUTTON_CONTENT